Zenas BioPharma获得了全球对Orelabrutinib的权利,并为MS和自动免疫试验争取了120M美元的资金。 Zenas BioPharma gained global rights to orelabrutinib and secured $120M in funding for MS and autoimmune trials.

Zenas BioPharma获得了1.2亿美元的融资,并从InnoCare Pharma获得了全球权利,为大中国和东南亚以外的多发性硬化症和其他自发性免疫条件开发大脑精液BTK抑制剂Oelabrutinib。 Zenas BioPharma secured $120 million in financing and obtained global rights from InnoCare Pharma to develop orelabrutinib, a brain-penetrant BTK inhibitor, for multiple sclerosis and other autoimmune conditions outside Greater China and Southeast Asia. 初级进步MS第3阶段试验正在进行中,二级进步MS第3阶段试验定于2026年初开始。 A Phase 3 trial for primary progressive MS is underway, with a second Phase 3 trial for secondary progressive MS set to begin in early 2026. 该公司还获得了两名新的自动免疫候选人(IL-17AA/AF抑制剂和TYK2抑制剂)的权利,两者都预计在2026年进入第一阶段试验。 The company also gained rights to two new autoimmune candidates, an IL-17AA/AF inhibitor and a TYK2 inhibitor, both expected to enter Phase 1 trials in 2026. 上一期第二阶段的数据表明,其功效和安全性很强。 Previous Phase 2 data showed strong efficacy and safety. Zenas 可能会支付高达 20 亿美元的里程碑和特许权使用费，预计这笔资金将支持运营到 2026 年底，并可能延长到 2027 年，并可能达到 7500 万美元的里程碑。 Zenas may pay up to $2 billion in milestones and royalties, and the funding is expected to support operations into late 2026, possibly extending into 2027 with a potential $75 million milestone. 股票增加16.35%,增至24.26美元。 Shares rose 16.35% to $24.26.